Table 1.
Baseline characteristics of 1,167 eyes of 640 infants treated for type 1 retinopathy of prematurity, stratified by modality of treatment and postmenstrual age at treatment.
Anti-VEGF, anti-vascular endothelial growth factor; PMA, post-menstrual age; ROP, retinopathy of prematurity.
| PMA < 36 weeks | PMA >= 36 weeks | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Laser
(N = 368 eyes) |
Anti-VEGF
(N = 90 eyes) |
p value |
Laser
(N = 635 eyes) |
Anti-VEGF
(N = 74 eyes) |
p value |
Laser
(N = 1003 eyes) |
Anti-VEGF
(N = 164 eyes) |
p value | |
| Birth weight (g) | 0.02 | 0.44 | 0.01 | ||||||
| Mean (SD) | 673.6 (138.0) | 620.9 (131.3) | 729.2 (207.4) | 702.9 (201.1) | 708.8 (186.8) | 657.9 (170.8) | |||
| Median | 650.0 | 610.0 | 682.0 | 655.0 | 670.0 | 628.0 | |||
| Range | (380.0–1235.0) | (390.0–875.0) | (380.0–1692.0) | (370.0–1273.0) | (380.0–1692.0) | (370.0–1273.0) | |||
| Gestational Age (weeks) | 0.40 | 0.99 | 0.12 | ||||||
| Mean (SD) | 24.2 (1.0) | 24.0 (1.4) | 25.3 (1.6) | 25.3 (1.7) | 24.9 (1.5) | 24.6 (1.7) | |||
| Median | 24.0 | 24.0 | 25.0 | 25.0 | 25.0 | 24.0 | |||
| Range | (22.0–28.0) | (22.0–27.0) | (22.0–31.0) | (22.0–32.0) | (22.0–31.0) | (22.0–32.0) | |||
| PMA at first type 1 treatment | 0.98 | 0.25 | 0.001 | ||||||
| Mean (SD) | 34.1 (1.0) | 34.1 (0.9) | 38.2 (2.0) | 37.8 (1.7) | 36.7 (2.6) | 35.8 (2.3) | |||
| Median | 34.0 | 34.0 | 38.0 | 37.0 | 36.0 | 35.0 | |||
| Range | (30.0–35.0) | (32.0–35.0) | (36.0–46.0) | (36.0–42.0) | (30.0–46.0) | (32.0–42.0) | |||
| Gender | 0.96 | 0.09 | 0.25 | ||||||
| Female | 158 (42.9%) | 39 (43.3%) | 293 (46.1%) | 24 (32.4%) | 451 (45.0%) | 63 (38.4%) | |||
| Male | 210 (57.1%) | 51 (56.7%) | 342 (53.9%) | 50 (67.6%) | 552 (55.0%) | 101 (61.6%) | |||
| Ethnicity | 0.73 | 0.07 | 0.52 | ||||||
| Hispanic or Latino | 35 (9.5%) | 9 (10.0%) | 59 (9.3%) | 2 (2.7%) | 94 (9.4%) | 11 (6.7%) | |||
| Not Hispanic or Latino | 175 (47.6%) | 48 (53.3%) | 397 (62.5%) | 42 (56.8%) | 572 (57.0%) | 90 (54.9%) | |||
| Unknown | 158 (42.9%) | 33 (36.7%) | 179 (28.2%) | 30 (40.5%) | 337 (33.6%) | 63 (38.4%) | |||
| Race | 0.27 | 0.21 | 0.04 | ||||||
| White/Caucasian | 194 (52.7%) | 50 (55.6%) | 348 (54.8%) | 33 (44.6%) | 542 (54.0%) | 83 (50.6%) | |||
| Asian/Asian American | 10 (2.7%) | 4 (4.4%) | 18 (2.8%) | 2 (2.7%) | 28 (2.8%) | 6 (3.7%) | |||
| Black/African American | 75 (20.4%) | 9 (10.0%) | 139 (21.9%) | 9 (12.2%) | 214 (21.3%) | 18 (11.0%) | |||
| American Indian/Alaskan Native | 6 (1.6%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) | 7 (0.7%) | 0 (0.0%) | |||
| Native Hawaiian/Other Pacific Islander | 2 (0.5%) | 0 (0.0%) | 4 (0.6%) | 0 (0.0%) | 6 (0.6%) | 0 (0.0%) | |||
| Other | 46 (12.5%) | 11 (12.2%) | 40 (6.3%) | 6 (8.1%) | 86 (8.6%) | 17 (10.4%) | |||
| Unknown | 35 (9.5%) | 16 (17.8%) | 82 (12.9%) | 21 (28.4%) | 117 (11.7%) | 37 (22.6%) | |||
| Greater than 1 race checked | 0 (0.0%) | 0 (0.0%) | 3 (0.5%) | 3 (4.1%) | 3 (0.3%) | 3 (1.8%) | |||
| Birth Location | 0.07 | 0.80 | 0.28 | ||||||
| Inborn | 158 (42.9%) | 52 (57.8%) | 373 (58.7%) | 45 (60.8%) | 531 (52.9%) | 97 (59.1%) | |||
| Outborn | 210 (57.1%) | 38 (42.2%) | 262 (41.3%) | 29 (39.2%) | 472 (47.1%) | 67 (40.9%) | |||
| Stage, Zone, Plus at type 1 ROP treatment | 0.08 | 0.14 | <0.001 | ||||||
| Stage 1,Zone I,Plus | 6 (1.6%) | 7 (7.8%) | 0 (0.0%) | 3 (4.1%) | 6 (0.6%) | 10 (6.1%) | |||
| Stage 2,Zone I,Plus | 11 (3.0%) | 5 (5.6%) | 3 (0.5%) | 1 (1.4%) | 14 (1.4%) | 6 (3.7%) | |||
| Stage 2,Zone II,Plus | 35 (9.5%) | 5 (5.6%) | 63 (9.9%) | 5 (6.8%) | 98 (9.8%) | 10 (6.1%) | |||
| Stage 3,Zone I,No plus | 15 (4.1%) | 6 (6.7%) | 6 (0.9%) | 2 (2.7%) | 21 (2.1%) | 8 (4.9%) | |||
| Stage 3,Zone I,Plus | 67 (18.2%) | 28 (31.1%) | 13 (2.0%) | 8 (10.8%) | 80 (8.0%) | 36 (22.0%) | |||
| Stage 3,Zone I,Pre-plus | 20 (5.4%) | 9 (10.0%) | 14 (2.2%) | 10 (13.5%) | 34 (3.4%) | 19 (11.6%) | |||
| Stage 3,Zone II,Plus | 205 (55.7%) | 30 (33.3%) | 494 (77.8%) | 45 (60.8%) | 699 (69.7%) | 75 (45.7%) | |||
| Type I ROP, Not specified, Not specified | 0 (0.0%) | 0 (0.0%) | 4 (0.6%) | 0 (0.0%) | 4 (0.4%) | 0 (0.0%) | |||
| Type I ROP,Not specified, Plus | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | 0 (0.0%) | 1 (0.1%) | 0 (0.0%) | |||
| Type I ROP,Zone II, Plus | 9 (2.4%) | 0 (0.0%) | 35 (5.5%) | 0 (0.0%) | 44 (4.4%) | 0 (0.0%) | |||
| Type I ROP,Zone II, Pre-plus | 0 (0.0%) | 0 (0.0%) | 2 (0.3%) | 0 (0.0%) | 2 (0.2%) | 0 (0.0%) | |||
| Anti-VEGF agent | |||||||||
| Bevacizumab | 85 (94.4%) | 62 (83.8%) | 147 (89.6%) | ||||||
| Ranibizumab | 5 (5.6%) | 12 (16.2%) | 17 (10.4%) | ||||||
P values were from logistic regression with generalized estimating equation to account for the correlation between eyes within the same infant.